Nextgen Bioscience Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 9

Nextgen Bioscience General Information

Description

Developer of a therapeutic drug designed for the treatment of fibrosis by conducting clinical trials. The company's platform includes candidate substances for three diseases, such as wet macular degeneration, non-alcoholic steatohepatitis, and pulmonary fibrosis, and also provides treatment for ocular fibrosis disease, enabling patients suffering from refractory fibrosis to get treatment for fibrosis disease, which has a medically underserved demand due to a lack of treatment.

Contact Information

Website
www.nextgenbio.co.kr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 17, Pangyo-ro 228beon-gil, Bundang-gu
  • 633 Sampyeong-dong, Pangyo Seven Venture Valley 2 Elantec-dong 2nd Floor Research Center
  • Seongnam, Gyeonggi 13487
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 17, Pangyo-ro 228beon-gil, Bundang-gu
  • 633 Sampyeong-dong, Pangyo Seven Venture Valley 2 Elantec-dong 2nd Floor Research Center
  • Seongnam, Gyeonggi 13487
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nextgen Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 01-Jan-2025 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series B) 11-Jul-2023 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 30-Jun-2020 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 01-Jul-2019 $5.12M $5.12M Completed Clinical Trials - Phase 1
1. Seed Round 01-Dec-2018 Completed Startup
To view Nextgen Bioscience’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Nextgen Bioscience Patents

  • 69

    Total Documents Applications and Grants

  • Total Patents Families

  • 28

    Granted

  • 25

    Pending

  • Expiring in next 12 mo

Nextgen Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260116902-A1 Novel compound as functional antagonist for s1pr1 and s1pr4 Pending 31-Oct-2024
WO-2026095688-A1 Novel compound as functional inhibitor against s1pr1 and s1pr4 Pending 31-Oct-2024
JP-2026517257-A Administration method of regulators targeting s1pr1 and s1pr4 Pending 15-May-2023
AU-2024271976-A1 Method for administering modulator targeting s1pr1 and s1pr4 Pending 15-May-2023
EP-4714468-A1 Method for administering modulator targeting s1pr1 and s1pr4 Pending 15-May-2023 A61P13/12
To view Nextgen Bioscience’s complete patent history, request access »

Nextgen Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nextgen Bioscience Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
A Ventures Venture Capital Minority
DAYLI Partners Venture Capital Minority
JX Partners Venture Capital Minority
Korea Development Bank VC-Backed Company Minority
Korea Investment Trust Management Asset Manager Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Nextgen Bioscience FAQs

  • When was Nextgen Bioscience founded?

    Nextgen Bioscience was founded in 2018.

  • Where is Nextgen Bioscience headquartered?

    Nextgen Bioscience is headquartered in Seongnam, South Korea.

  • What is the size of Nextgen Bioscience?

    Nextgen Bioscience has 15 total employees.

  • What industry is Nextgen Bioscience in?

    Nextgen Bioscience’s primary industry is Drug Discovery.

  • Is Nextgen Bioscience a private or public company?

    Nextgen Bioscience is a Private company.

  • What is Nextgen Bioscience’s current revenue?

    The current revenue for Nextgen Bioscience is .

  • How much funding has Nextgen Bioscience raised over time?

    Nextgen Bioscience has raised $21.7M.

  • Who are Nextgen Bioscience’s investors?

    A Ventures, DAYLI Partners, JX Partners, Korea Development Bank, and Korea Investment Trust Management are 5 of 9 investors who have invested in Nextgen Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process